Biocon Limited — Q3 FY26
Biocon delivered a solid Q3 FY26 with group revenue of ₹4,173 crore (+9% YoY) and EBITDA of ₹951 crore (+21% YoY), driven by strong biosimilar margins (28% vs 21% last year) and...
bullish
high
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q2 FY26
Biosimilar R&D spend at 7-9% of revenue
Management expects R&D investment for biosimilars to remain in the 7-9% range of segment revenue for FY26.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q2 FY26
Generics R&D spend at 8-10% of revenue
Generics R&D spend is expected to be in the 8-10% range of segment revenue.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q2 FY26
Generics gross margin improvement in H2
Gross margins in generics are expected to improve in the second half of FY26, driven by new product launches.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q2 FY26
Syngene maintains FY26 annual guidance
Syngene's performance in H1 is in line with expectations, and the company is maintaining its annual guidance for FY26.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1